Dogwood Therapeutics closed at $1.03 on Nov 4, down 0.96%, within 0.0% of its 52-week closing low. Volume of 123.5K shares was 1.41× its 20-day average (above normal).
Split-adjusted performance: -32.2% over one month, -37.6% over six months, -83.4% over one year.
Short interest was 62.4K shares at the Oct 15 settlement, up 60.4% from the prior report (0.7% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | |
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | Compare |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
| GRCEGrace Therapeutics | $1.81 | −1.63% | −23.6% | — | — | — | $38.1M | Compare |
| VERUVeru | $2.20 | +1.85% | −0.9% | — | — | — | $37.5M | Compare |
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | Compare |
| SERSerina Therapeutics | $1.69 | −7.65% | −7.7% | −100.0% | — | — | $42.9M | Compare |
| BTMDBiote | $1.23 | +9.82% | −44.1% | −9.5% | −14.8% | 6.0 | $35.3M | Compare |
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | Compare |
No recent articles focused on Dogwood Therapeutics.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
